CRISPR, a child of modern biology, is growing by leaps and bounds. It has grown from a strange part of the bacterial immune system into a tool for treating genetic diseases, improving micro-organisms, improvement of food production and pest control. Since then, scientists have adopted this tool to edit the genes and began to use it in mammalian cells, CRISPR was barricaded in cell membranes. The technology for editing genes works his magic, cutting the pieces of faulty DNA and inserting healthy replacement. All of these steps by cutting and pasting segments took place in living cells. Still.
Last week in the journal CRISPR Journal a study was published finally freed TUESDAY from his cell in prison. Replacing the component “Treasury” CRISPR alternative version, scientists from the Institute for the editing of genes in Delaware has developed a new system called CRISPR, which can cut free-floating DNA in vitro.
To assist in carrying out the reaction vial with the cell extracts: a set of enzymes and other biomolecules for work CRISPR.
What is breakthrough?
Diagnostic miracle
To get CRISPR to work outside the cage it may seem strange academic task, but in developing the system, researchers kept in mind two specific goals.
First, this tool allows scientists to simultaneously make multiple genetic knockouts, while previous versions were limited to the editing of DNA within a single gene. This is good news for personalized medicine, especially diagnosis of cancer; many cancers have mutations in several places that respond to different treatment in different ways.
Before treatment, doctors often send a biopsy sample of the tumor for DNA sequencing. This important step helps to identify many of the genetic mutations leading to the growth or proliferation of a particular tumor.
Using the new tool, scientists can accurately simulate these mutations into synthetic DNA fragments in vitro, essentially recreating a cancer in a safe, controlled environment. This gives scientists access to biological pathways affected by the mutations, and could help in the creation of personalized treatment strategies.
Even more impressive, this kind of diagnostics can be held in just one day. “This is especially important for the diagnosis related to the cancer, when it is a matter of minutes or hours,” says study author Dr. Eric Kmiec.
Kmiec not the first saw CRISPR diagnostic tool. That in addition to gene therapy, CRISPR, can show itself powerfully in the diagnosis, it was clear long ago. Earlier we wrote that two teams of scientists presented the test DETECTR and SHERLOCK that effectively hunt for viruses, zika, dengue or dangerous strains of HPV that lead to cervical cancer.
Kmiec claims that his invention requires a “significantly” less time to confirm the presence of cancer outside the body, mainly because of the ability to make several versions at the same time.
Realizing the potential and profitability of CRISPR as a diagnostic tool, Kmiec and his colleagues are already looking for a commercial partner to develop the technology “CRISPR-on-a-chip” for diagnosing cancer.
If you put aside the immediate applications, the team also hopes to expand the therapeutic potential of CRISPR to a much wider range of human diseases. Existing CRISPR tools are ideal for the treatment of diseases caused by mutations in a single gene such as sickle cell anemia or Huntington’s disease. But since the work Cieca aimed at several genes simultaneously, it can potentially lead to treatment of diseases with more complex genetic origin of multiple mutations in multiple genes — if these mutations are well characterized.
Through the lens
Insulation CRISPR in vitro has another benefit: it allows scientists to clearly understand what happens before, during and after editing. And because clinical trials CRISPR actively promoted, it is important to understand how to make technology more accurate and effective.
CRISPR has already achieved a lot, but the inconvenient truth is that scientists still are not sure how the tool works, getting in the cage. How the tools interact with other biocomponents in a cage? He cuts off only the target DNA or its pair of scissors can go berserk in certain circumstances?
“When you work with CRISPR in the cell you are working in a black box, which can not observe the mechanisms that make these amazing things,” says Kmiec. “You can see the results, i.e. changes in genes, but how did you come to that — not necessarily, and this is important in order to ensure the safety of CRISPR to treat patients.”
Limiting CRISPR series of biochemical reactions in a test tube, scientists propose a way to consider the complex molecular interactions which take place during the incision of DNA, gene replacement, and other processes. Approach exclusively reductionist. But it allows cell-free system to work like Arduino, to experiment with the possibilities of CRISPR and create new biological tools, which are hard to imagine.
Substitution
Institute edit genes in almost immediately faced with the problem, developing cell-free system.
Problem child was Cas9, scissor protein, which is used in CRISPR systems. When the scientists mixed his DNA with plasmid — circular DNA, which scientists often use for gene delivery to cells in vitro, the protein was completely inactive.
It turned out that Cas9, to be replaced by Cpf1 (aka Cas12a), another member of the growing library of Cas proteins. Originally opened in 2015, Cpf1 has already proven useful in creating transgenic mice and the adjustment of the mutation that causes muscular dystrophy. Not so long ago Cpf1 used in the system DETECTR to fight against viruses that cause cancer. This protein bright future: the company Editas, editing genes has licensed it for further development in 2016.
The exchange worked. The CRISPR system-Cpf1 came into effect in a test tube. In several experiments, scientists have proven that is free from cells, the system can replicate most of the revisions CRISPR makes inside the cage. Remarkably, the scissors worked a little as Cas9. When Cas9 makes a cut, it leaves Everglade “cut ends” on the cut DNA. This complicates the commissioning of new pieces of genetic material. Because the ends are very smooth, the instrumentation requires precise alignment of the replacement block DNA so that it slid into place.
Conversely, Cpf1 leaves “sticky” ends. These pieces of DNA act as shoulders, as if tape support for capturing a substitute DNA. Perhaps that is why Cpf1 works better than Cas9, in vitro, but this remains to be tested.
System Kieza — just one example of how far advanced CRISPR. As CRISPR continues to grow, its developers promise us a lot, we even can’t imagine.
CRISPR-on-a-chip can serve as a tool for cancer diagnosis
Ilya Hel